News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
853,097 Results
Type
Article (77400)
Company Profile (347)
Press Release (775317)
Multimedia
Podcasts (270)
Webinars (41)
Section
Business (258900)
Career Advice (3856)
Deals (38945)
Drug Delivery (222)
Drug Development (88930)
Employer Resources (211)
FDA (18505)
Job Trends (17119)
News (386099)
Policy (38677)
Tag
2027 BioCapital Elite (1)
2027 BioCapital Standard (5)
2027 BioMidwest Digital (1)
2027 BioMidwest Elite (2)
2027 BioMidwest Standard (3)
2027 Bio NC Standard (3)
2027 Biotech Bay Elite (4)
2027 Biotech Bay Standard (11)
2027 Biotech Beach Digital (1)
2027 Biotech Beach Elite (3)
2027 Biotech Beach Standard (7)
2027 Genetown Elite (6)
2027 Genetown Standard (12)
2027 Pharm Country Digital (2)
2027 Pharm Country Elite (2)
2027 Pharm Country Premier (1)
2027 Pharm Country Standard (11)
40 Under 40 (1)
Academia (3095)
Academic (2)
Accelerated approval (71)
ADA (51)
Adcomms (44)
Allergies (226)
Alliances (55893)
ALS (273)
Alzheimer's disease (2096)
Antibody-drug conjugate (ADC) (686)
Approvals (19023)
Artificial intelligence (1012)
ASCO (345)
Autoimmune disease (463)
Automation (78)
Bankruptcy (393)
Belgium (17)
Best Places to Work (12624)
BIO (79)
Biologics (35)
BIOSECURE Act (23)
Biosimilars (295)
BioSpace Insights (257)
Biotechnology (245)
Bispecific (11)
Bladder cancer (231)
Brain cancer (97)
Breast cancer (921)
Cancer (7445)
Cardiovascular disease (645)
Career advice (3338)
Career pathing (63)
CAR-T (431)
CDC (79)
CDMO (201)
Celiac Disease (4)
Cell-line development (2)
Cell therapy (1175)
Cervical cancer (62)
Clinical research (77956)
Collaboration (2728)
Commercialization (26)
Company closure (10)
Compensation (1838)
Complete response letters (124)
COVID-19 (3062)
CRISPR (140)
CRO (1)
C-suite (1621)
Cystic fibrosis (179)
Data (10033)
Decentralized trials (4)
Denatured (106)
Depression (221)
Dermatology (164)
Diabetes (801)
Diagnostics (7832)
Digital health (79)
Diversity (14)
Diversity, equity & inclusion (49)
Drug discovery (505)
Drug pricing (251)
Drug shortages (39)
Duchenne muscular dystrophy (374)
Earnings (99555)
Editorial (84)
Employer branding (27)
Employer resources (182)
Events (136638)
Executive appointments (1342)
Eye disease (6)
FDA (23312)
Fibrodysplasia Ossificans Progressiva (13)
Fragile X (2)
Friedreich's ataxia (26)
Frontotemporal dementia (39)
Funding (2239)
Gene editing (300)
Generative AI (96)
Gene therapy (935)
GLP-1 (1365)
Government (5568)
Grass and pollen (8)
Guidances (438)
Healthcare (21363)
Hematology (197)
HIV (114)
Huntington's disease (79)
Idiopathic pulmonary fibrosis (4)
IgA nephropathy (140)
Immunology and inflammation (415)
Immuno-oncology (145)
Indications (262)
Infectious disease (3493)
Inflammatory bowel disease (256)
Inflation Reduction Act (17)
Influenza (159)
Intellectual property (369)
Interviews (753)
IPO (17806)
IRA (61)
Job creations (4793)
Job search strategy (2667)
JPM (73)
Kidney cancer (28)
Kidney disease (117)
Labor market (141)
Layoffs (714)
Leadership (66)
Legal (9669)
Licensing (52)
Liver cancer (117)
Longevity (50)
Lung cancer (1024)
Lung diease (18)
Lymphoma (532)
Machine learning (74)
Management (71)
Manufacturing (1531)
Marketing (16)
MASH (243)
Medical affairs (3)
Medical device (15397)
Medtech (15680)
Mergers & acquisitions (22630)
Metabolic disorders (2039)
mRNA (320)
Multiple sclerosis (235)
Multispecific (3)
NASH (24)
Netherlands (14)
Neurodegenerative disease (593)
Neuropsychiatric disorders (148)
Neuroscience (4139)
Neurotech (1)
NextGen: Class of 2026 (7598)
Non-profit (5166)
Now hiring (96)
Obesity (968)
Opinion (399)
Ovarian cancer (278)
Pain (326)
Pancreatic cancer (419)
Parkinson's disease (472)
Partnered (47)
Patents (772)
Patient advocacy (2)
Patient recruitment (960)
Patient selection (37)
Peanut (77)
People (67352)
Peptides (15)
Pharmaceutical (68)
Pharmacy benefit managers (41)
Phase 1 (24156)
Phase 2 (33924)
Phase 3 (25723)
Pipeline (12854)
Policy (418)
Postmarket research (3167)
Preclinical (10561)
Press Release (72)
Prostate cancer (383)
Psychedelics (95)
Radioligand (2)
Radiopharmaceuticals (426)
Rare diseases (1521)
Real estate (7127)
Recruiting (83)
Regenerative medicine (11)
Regulatory (30713)
Reports (93)
Research institute (2797)
Resumes & cover letters (611)
Rett syndrome (55)
RNA editing (36)
RSV (102)
Schizophrenia (215)
Series A (393)
Series B (274)
Service/supplier (15)
Sickle cell disease (139)
Special edition (36)
Spinal muscular atrophy (197)
Sponsored (59)
Startups (4211)
State (2)
Stem cells (1)
Stomach cancer (22)
Substance use disorders (21)
Supply chain (163)
Switzerland (1)
Tariffs (105)
The Weekly (161)
Vaccines (1394)
Venture capital (166)
Weight loss (649)
Wet AMD (4)
Women's health (174)
Worklife (27)
Date
Today (113)
Last 7 days (703)
Last 30 days (2758)
Last 365 days (33302)
2026 (25426)
2025 (32417)
2024 (37488)
2023 (42549)
2022 (53909)
2021 (58694)
2020 (57641)
2019 (51287)
2018 (39075)
2017 (36739)
2016 (37410)
2015 (44123)
2014 (39289)
2013 (35134)
2012 (35535)
2011 (35511)
2010 (33852)
Location
Africa (1204)
Alabama (115)
Alaska (7)
Arizona (448)
Arkansas (17)
Asia (50879)
Australia (8680)
California (16194)
Canada (4498)
China (1892)
Colorado (697)
Connecticut (724)
Delaware (502)
Europe (115845)
Florida (2479)
Georgia (526)
Hawaii (5)
Idaho (70)
Illinois (1399)
India (139)
Indiana (742)
Iowa (31)
Japan (729)
Kansas (156)
Kentucky (67)
Louisiana (67)
Maine (96)
Maryland (1931)
Massachusetts (11721)
Michigan (448)
Minnesota (889)
Mississippi (7)
Missouri (181)
Montana (37)
Nebraska (31)
Nevada (180)
New Hampshire (92)
New Jersey (4269)
New Mexico (38)
New York (4248)
North Carolina (2115)
North Dakota (12)
Northern California (8229)
Ohio (516)
Oklahoma (31)
Oregon (51)
Pennsylvania (3108)
Puerto Rico (37)
Rhode Island (58)
South America (1588)
South Carolina (99)
South Dakota (2)
Southern California (6449)
Tennessee (268)
Texas (2680)
United States (57538)
Utah (492)
Vermont (2)
Virginia (412)
Washington D.C. (89)
Washington State (1304)
West Virginia (4)
Wisconsin (186)
Wyoming (5)
853,097 Results for "merck and co".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Eye disease
Merck’s experimental eye drug matches Roche’s VEGF inhibitor but safety concerns emerge
Analysts were keen to see a new modality compete with Roche’s approved drug Lucentis in the late-stage trial but new safety issues could complicate the future for Merck’s candidate.
September 24, 2026
·
2 min read
·
Annalee Armstrong
Vaccines
Vaxcyte rises as pneumococcal shot establishes ‘new competitive moat’ vs. Pfizer, Merck
VAX-31 beat Pfizer and Merck’s established pneumococcal conjugate vaccines in a Phase 3 trial, exceeding investors’ most ambitious scenario and setting Vaxcyte up to challenge the Big Pharmas in a market worth $8 billion.
October 5, 2026
·
2 min read
·
Annalee Armstrong
Drug Development
Merck’s antibody impresses with ‘highly competitive’ data in chronic skin disease
Merck has revealed detailed data for tulisokibart from a mid-stage trial in hidradenitis suppurativa that analysts say could help carve out a place in a crowded market that already includes AbbVie’s Humira and UCB’s Bimzelx.
October 1, 2026
·
2 min read
·
Tristan Manalac
Lung cancer
Summit, Akeso’s ivonescimab bests Merck’s Keytruda in China trial—again
New Phase 3 data show that Summit Therapeutics and Akeso’s PD-1/VEGF therapy improved overall survival in patients with a type of lung cancer as compared to Merck’s Keytruda but the results will need to be replicated in non-Chinese patients.
September 3, 2026
·
2 min read
·
Annalee Armstrong
Cancer
5 drugmakers chasing Merck and Moderna in the cancer vaccine race
Following their blowout win in melanoma last month, Merck and Moderna are leading the way among a new crop of personalized cancer vaccines. Here are five companies with similar therapies hoping to break through where others have previously failed.
September 14, 2026
·
9 min read
·
Tristan Manalac
Business
BMO most bullish on Merck’s, bearish on BMS’ plans to contend with patent cliffs
BMO Capital Markets is more impressed by Merck’s plans to replace lost Keytruda revenue than on Bristol Myers Squibb’s efforts to fill the expected void that will come from loss of exclusivity for both Opdivo and Eliquis.
October 2, 2026
·
4 min read
·
Gabrielle Masson
Lung cancer
Merck, Daiichi Sankyo retract accelerated approval request for lung cancer ADC
Merck and Daiichi Sankyo’s withdrawal of an accelerated approval request for the antibody-drug conjugate ifinatamab deruxtecan is a “net positive” for rivals like GSK and Roche, according to RBC Capital Markets.
September 28, 2026
·
2 min read
·
Tristan Manalac
Earnings
Merck’s $10.8B Prometheus deal delivers another win—plus a Phase 2b miss
The anti-TL1A antibody from Merck’s 2023 Prometheus buy delivered positive mid-stage results in a skin condition but failed in a certain type of lung disease, the Big Pharma revealed alongside second-quarter earnings.
August 4, 2026
·
3 min read
·
Gabrielle Masson
Manufacturing
Moderna and Merck’s mRNA success fuels focus on ‘scaling out and scaling down’
After mastering mass-market mRNA production during the pandemic, the industry now needs to achieve the timely delivery of individualized vaccines to thousands of patients.
September 8, 2026
·
2 min read
·
Nick Paul Taylor
Licensing
Merck inks up to $2.13B deal to dine with SciBrunch, gain rights to preclinical KRAS inhibitor
Merck continues to diversify its cancer efforts as the clock ticks down on Keytruda’s patent, picking up rights to a preclinical oncology asset in a deal that could exceed $2 billion.
September 28, 2026
·
2 min read
·
Gabrielle Masson
1 of 85,310
Next
